Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe−). Therefore, we assessed whether HCC risk is increased in non-cirrhotic CHBe− patients who discontinue compared to those remaining on NAs.

Click here to read the article